Computational Characterization of Structural Role of the Non-active Site Mutation M36I of Human Immunodeficiency Virus Type 1 Protease

This publication has 46 references indexed in Scilit:

• Novel bis -Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro
  Antimicrobial Agents and Chemotherapy, 2003
• Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
  AIDS, 2000
• BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents
  Antimicrobial Agents and Chemotherapy, 2000
• Protease sequences from HIV-1 group M subtypes A???H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide
  AIDS, 2000
• Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy
  The Journal of Infectious Diseases, 1995
• ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
  Proceedings of the National Academy of Sciences, 1995
• L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
  Proceedings of the National Academy of Sciences, 1994
• Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
  Antiviral Research, 1991
• Active human immunodeficiency virus protease is required for viral infectivity.
  Proceedings of the National Academy of Sciences, 1988
• VIRAL PROTEINASES
  Annual Review of Biochemistry, 1988